Finnhub•2026-04-22
Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026MDGL — Madrigal Pharmaceuticals Inc
NASDAQ · Biotechnology · Biotechnology
$527.69-7.66%Market cap12.55B
- Latest Close
- $527.69
- 30-Day Move
- -7.7%
- Market Cap
- $12.5B
- Shares Outstanding
- 22,940,000
- P/B Ratio
- 21.94
- ROE
- -47.8%
NASDAQ:MDGLBiotechnology / BiotechnologyDelayed public snapshot
Madrigal Pharmaceuticals Inc
A read-only Alphactor snapshot forMadrigal Pharmaceuticals Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$527.69
30-Day Move
-7.7%
Market Cap
$12.5B
Shares Outstanding
22,940,000
P/B Ratio
21.94
ROE
-47.8%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$527.69
-7.7%last 90 delayed daily bars
Market cap$12.5B
90D High
$615.00
90D Low
$416.21
Avg Volume
352,237
What stands out
Gross margin is running at 94.1%, which gives a quick read on operating quality before you open the full model.
Net margin is -30.1%, useful for comparing MDGL against peers in Biotechnology.
MDGL is down 7.7% over the last 30 trading days shown on this page.
Latest operating income is $-60M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$202.40
Rule of 40
411.9%
Dark Pool Short %
47.7%
Fundamentals snapshot
Latest Close
$527.69
30-Day Move
-7.7%
Market Cap
$12.5B
Shares Outstanding
22,940,000
P/B Ratio
21.94
ROE
-47.8%
ROA
-22.9%
Gross Margin
94.1%
Operating Margin
-31.6%
Net Margin
-30.1%
Debt / Equity
0.56
Current Ratio
4.01
Latest Revenue
$321M
Financial statement snapshot
Revenue
$321M
Gross Profit
$297M
Operating Income
$-60M
Net Income
$-59M
Gross Margin
9414.0%
Net Margin
-3008.0%
Current Ratio
4.01
Debt / Equity
0.56
Valuation snapshot
Fair Value
$202.40
Upside / Downside
-61.6%
Signal
Overvalued
Implied Growth
--
EV/Rev
$202.40
Growth Assumption
5.0%
Discount Rate
8.4%
Terminal Growth
2.0%
Base FCF
--
Valuation spread
Current Price
$527.69
Composite Fair Value
$202.40
EV/Rev
$202.40
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative FCF — company is cash-flow negative. Reverse DCF requires positive cash flows.
Quality snapshot
Altman Z
10.00
Safe
Piotroski
3
Weak (0-3)
Cash Conversion
0.66x
Rule of 40
411.9%
Elite
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $0 | $-294M | $-295M | $-225M |
| 2023-12-31 | $0 | $-380M | $-374M | $-326M |
| 2024-12-31 | $180M | $-498M | $-466M | $-462M |
| 2025-12-31 | $958M | $-300M | $-288M | $-193M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Finnhub•2026-04-21
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$0
Sell Value
$25M
Buys
0
Sells
77
Buy Value
$0
Sell Value
$25M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-06 | Dier Mardi | Sell | 40 | $437.65 |
| 2026-03-06 | Dier Mardi | Sell | 80 | $436.69 |
| 2026-03-06 | Dier Mardi | Sell | 80 | $435.31 |
| 2026-03-06 | Dier Mardi | Sell | 160 | $434.20 |
| 2026-03-06 | Dier Mardi | Sell | 116 | $432.56 |
| 2026-03-06 | Dier Mardi | Sell | 120 | $430.90 |
| 2026-03-06 | Dier Mardi | Sell | 40 | $429.58 |
| 2026-03-06 | Dier Mardi | Sell | 160 | $429.00 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 574,387 | 0.03% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 452,264 | 0.02% | 2026-02-28 |
| JANUS INVESTMENT FUND-Janus Henderson Forty Fund | 429,415 | 0.02% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 412,294 | 0.02% | 2025-12-31 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 398,129 | 0.02% | 2026-01-31 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 205,480 | 0.01% | 2026-03-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 200,666 | 0.01% | 2025-12-31 |
| JANUS INVESTMENT FUND-Janus Henderson Contrarian Fund | 191,727 | 0.01% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Qube Research & Technologies
Filed 2026-02-17
--
--
Vanguard Group
Filed 2026-01-29
$1.1B
-0.2%
BlackRock
Filed 2024-08-13
$400M
--
Geode Capital Management
Filed 2026-02-09
$263M
+1.2%
FMR LLC (Fidelity)
Filed 2026-02-17
$256M
+9.5%
Invesco
Filed 2026-02-19
$213M
+21.9%
Goldman Sachs
Filed 2026-02-10
$178M
-20.8%
Dark-pool activity snapshot
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.